BioNTech SE (NASDAQ:BNTX) Receives $142.72 Consensus Target Price from Analysts

Shares of BioNTech SE (NASDAQ:BNTX) have been assigned a consensus recommendation of “Moderate Buy” from the seventeen ratings firms that are presently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation, thirteen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $142.72.

Several research analysts have commented on BNTX shares. The Goldman Sachs Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating and raised their target price for the stock from $90.00 to $137.00 in a report on Friday, November 8th. TD Cowen decreased their target price on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a report on Tuesday, November 5th. Truist Financial started coverage on shares of BioNTech in a report on Friday, January 10th. They issued a “buy” rating and a $172.00 target price for the company. Berenberg Bank began coverage on shares of BioNTech in a report on Tuesday, November 19th. They issued a “buy” rating and a $130.00 target price for the company. Finally, Wells Fargo & Company began coverage on shares of BioNTech in a report on Wednesday, December 11th. They set an “overweight” rating and a $170.00 price target for the company.

BioNTech Stock Performance

Shares of BNTX opened at $119.83 on Monday. BioNTech has a one year low of $76.53 and a one year high of $131.49. The company has a 50-day moving average of $117.22 and a two-hundred day moving average of $109.62. The stock has a market cap of $28.73 billion, a price-to-earnings ratio of -57.06 and a beta of 0.17. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21.

Institutional Trading of BioNTech

A number of institutional investors have recently added to or reduced their stakes in BNTX. Jones Financial Companies Lllp lifted its stake in BioNTech by 110.3% in the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock valued at $53,000 after acquiring an additional 246 shares during the last quarter. Planning Capital Management Corp lifted its stake in BioNTech by 45,000.0% in the third quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after acquiring an additional 450 shares during the last quarter. Blue Trust Inc. lifted its stake in BioNTech by 491.1% in the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after acquiring an additional 388 shares during the last quarter. GAMMA Investing LLC lifted its stake in BioNTech by 21.7% in the third quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock valued at $74,000 after acquiring an additional 111 shares during the last quarter. Finally, Quintet Private Bank Europe S.A. lifted its stake in BioNTech by 823.5% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock valued at $88,000 after acquiring an additional 700 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.